CVR number 15731176
Industry 46.4620 Wholesale of pharmaceutical goods

BK MEDICAL ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Loading...
Bankruptcy Risk 
2019
2019/7
2020
2020/7
2021
2021/7
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.3% 1.8% 0.7% 0.7% 0.4%  
Credit score (0-100)  100 72 95 95 100  
Credit rating  AAA A AA AA AAA  
Credit limit (mDKK)  40.9 0.0 16.8 39.5 43.7  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (mDKK) 
2019
2019/7
2020
2020/7
2021
2021/7
2022
2022/12
2023
2023/12
Net sales  408 357 495 1,165 936  
Gross profit  223 184 260 469 340  
EBITDA  64.5 -23.6 50.8 90.2 61.3  
EBIT  64.5 -23.6 50.8 90.2 61.3  
Pre-tax profit (PTP)  69.5 -26.8 72.5 205.2 70.6  
Net earnings  60.3 -5.4 62.8 183.8 55.4  
Pre-tax profit without non-rec. items  69.5 -26.8 72.5 205 70.6  
 
See the entire income statement

Balance sheet (mDKK) 
2019
2019/7
2020
2020/7
2021
2021/7
2022
2022/12
2023
2023/12
Tangible assets total  104 101 102 112 115  
Shareholders equity total  332 29.8 92.5 276 332  
Interest-bearing liabilities  1.7 365 246 212 222  
Balance sheet total (assets)  415 468 437 652 726  
Net Debt  -2.1 360 220 182 207  
 
See the entire balance sheet

Volume 
2019
2019/7
2020
2020/7
2021
2021/7
2022
2022/12
2023
2023/12
Net sales  408 357 495 1,165 936  
Net sales growth  0.4% -12.5% 38.8% 135.2% -19.6%  
Gross profit  223 184 260 469 340  
Gross profit growth  -9.5% -17.8% 41.4% 80.8% -27.6%  
Employees  130 145 171 252 291  
Employee growth %  0.0% 11.5% 17.9% 47.4% 15.5%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  415 468 437 652 726  
Balance sheet change%  13.0% 12.6% -6.6% 49.1% 11.4%  
Added value  64.5 -23.6 50.8 90.2 61.3  
Added value %  15.8% -6.6% 10.3% 7.7% 6.5%  
Investments  -28 49 4 34 19  
Net sales trend  2.0 -1.0 1.0 2.0 -1.0  
EBIT trend  4.0 -1.0 1.0 2.0 3.0  

Profitability 
2019
2019/7
2020
2020/7
2021
2021/7
2022
2022/12
2023
2023/12
EBITDA %  15.8% -6.6% 10.3% 7.7% 6.5%  
EBIT %  15.8% -6.6% 10.3% 7.7% 6.5%  
EBIT to gross profit (%)  28.9% -12.8% 19.6% 19.2% 18.0%  
Net Earnings %  14.8% -1.5% 12.7% 15.8% 5.9%  
Profit before depreciation and extraordinary items %  14.8% -1.5% 12.7% 15.8% 5.9%  
Pre tax profit less extraordinaries %  17.0% -7.5% 14.6% 17.6% 7.5%  
ROA %  17.8% -3.0% 16.7% 45.6% 10.7%  
ROI %  21.8% -3.7% 20.5% 57.8% 13.4%  
ROE %  20.0% -3.0% 102.7% 99.6% 18.2%  

Solidity 
2019
2019/7
2020
2020/7
2021
2021/7
2022
2022/12
2023
2023/12
Equity ratio %  80.1% 6.5% 21.4% 42.9% 46.4%  
Relative indebtedness %  19.8% 122.8% 68.5% 29.9% 38.4%  
Relative net indebtedness %  18.9% 121.3% 63.3% 27.3% 36.8%  
Net int. bear. debt to EBITDA, %  -3.2% -1,526.0% 433.5% 201.2% 337.5%  
Gearing %  0.5% 1,222.0% 265.5% 76.6% 67.0%  
Net interest  0 0 0 0 0  
Financing costs %  16.2% 7.3% 1.1% 18.7% 1.5%  

Liquidity 
2019
2019/7
2020
2020/7
2021
2021/7
2022
2022/12
2023
2023/12
Quick Ratio  3.0 3.2 1.7 0.7 1.1  
Current Ratio  3.2 3.3 2.1 1.6 1.9  
Cash and cash equivalent  3.8 5.1 25.4 30.2 15.3  

Capital use efficiency 
2019
2019/7
2020
2020/7
2021
2021/7
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  47.2 41.7 42.6 17.3 25.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  58.5% 67.9% 40.6% 32.8% 46.8%  
Net working capital  163.6 169.7 107.4 141.6 206.1  
Net working capital %  40.1% 47.6% 21.7% 12.2% 22.0%  

Employee efficiency 
2019
2019/7
2020
2020/7
2021
2021/7
2022
2022/12
2023
2023/12
Net sales / employee  3 2 3 5 3  
Added value / employee  0 -0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 -0 0 0 0  
EBIT / employee  0 -0 0 0 0  
Net earnings / employee  0 -0 0 1 0